SynDermix

Executive Summary

SynDermix is a Swiss holding company established in 2018 that acquires and develops life science assets across MedTech, Pharma, Biotech, and Cosmeceuticals. Its portfolio includes subsidiaries focused on drug-free medical devices (e.g., for wound healing or dermatology), topical nitric oxide formulations for skin conditions, and plant lectin-based therapies for inflammatory or infectious diseases. The company leverages an asset-centric model to incubate early-stage innovations through initial development and validation, aiming to facilitate licensing or acquisition exits. While still private and in early revenue stages, SynDermix's diversified approach mitigates risk across multiple therapeutic areas and technologies. The drug-free device and nitric oxide platforms are closer to clinical validation, while plant lectin research remains preclinical. The company's Lausanne base provides access to European research networks and regulatory pathways. Key challenges include execution risk across distinct programs and reliance on partnership funding for later-stage trials. However, the portfolio's breadth offers multiple value inflection points in the near to medium term.

Upcoming Catalysts (preview)

• Q3 2026CE Mark approval for a drug-free medical device subsidiary65% success
• Q4 2026Initiation of a Phase 2 clinical trial for topical nitric oxide formulation40% success
• TBDPreclinical proof-of-concept data for plant lectin therapy30% success